{"id":854,"date":"2025-06-14T18:27:58","date_gmt":"2025-06-14T18:27:58","guid":{"rendered":"http:\/\/wmtc2006.com\/?p=854"},"modified":"2025-06-14T18:27:58","modified_gmt":"2025-06-14T18:27:58","slug":"limiting-the-number-of-disease-severity-and-qol-questionnaires-in-use-and-standardising-implementation-can-aid-in-assessing-outcome-measures-across-clinical-trials-and-allow-for-better-data-i","status":"publish","type":"post","link":"https:\/\/wmtc2006.com\/?p=854","title":{"rendered":"\ufeffLimiting the number of disease severity and QoL questionnaires in use and standardising implementation can aid in assessing outcome measures across clinical trials and allow for better data interpretation, comparability and clinical application of results"},"content":{"rendered":"<p>\ufeffLimiting the number of disease severity and QoL questionnaires in use and standardising implementation can aid in assessing outcome measures across clinical trials and allow for better data interpretation, comparability and clinical application of results. (11.3%), and antidrug antibody levels (7.6%) being frequently evaluated. A small portion of trials evaluated QoL (26.5% of studies), with the autoimmune bullous quality of life being the most common (15.1%), however QoL utilization as an end result measure has been increasing since 2015 (61.1% of trials since). Standardising the use of validated end result measurements <a href=\"http:\/\/www.cetel.org\/angel_poetry.html\">Rabbit Polyclonal to TRERF1<\/a> allows for better data interpretation, comparability and clinical application of results. What is already known? Pemphigus is a group of potentially lifethreatening autoimmunemediated blistering diseases with high mortality and reduced quality of life (QoL). Common clinical efficacy end result measures include disease control, relapse prevention and reduced dependency on corticosteroids. What does this study add? The use of standardized end result measurements including the pemphigus disease area index and antidesmoglein 1 and 3 levels have been increasing longitudinally, while the autoimmune bullous skin disorder intensity score has declined in favourability. Despite the profound impact on QoL, only 26.5% of trials included a QoL measurement as an outcome measurement, with the autoimmune bullous quality of life being most commonly used. == 1. INTRODUCTION == Pemphigus is usually a group of Efonidipine rare, chronic autoimmune blistering diseases characterised by mucocutaneous lesions and very easily rupturing cutaneous Efonidipine bullae affecting nearly 5.2 per 100 000 people in the United States.1Autoantibody production against desmogleins, a family of desmosomal cadherins involved in celltocell adhesion of keratinocytes, results in blister formation. The two most common subtypes of pemphigus include pemphigus vulgaris (PV), which primarily targets desmoglein 3 with mucosal involvement, as well as pemphigus foliaceous (PF), which primarily targets desmoglein 1, generally without mucosal involvement.2,3Pemphigus is associated with high morbidity and can be fatal due to severe blistering, secondary infections and malnutrition, with mortality rates up to 515% yearly.4Current treatment options for pemphigus include systemic glucocorticoid therapy, immunosuppressive drugs and targeted immunotherapy with antiB cell monoclonal antibodies such as rituximab.3Despite new therapeutic advances, longterm pemphigus treatment remains an unmet medical need. Pemphigus patients often suffer increased risks of contamination due to prolonged steroid use, and disease severity fluctuates due to disease progression\/relapse, thereby necessitating the need for objective disease scoring systems. With limited longterm efficacious treatment options, the variance in end result steps in pemphigus clinical trials makes therapeutic comparisons between studies challenging. Additionally, pemphigus is usually associated with high physical, emotional and social distress with as high as 77% of patients experiencing stress and depressive disorder.5,6Quality of life (QoL) assessments in pemphigus clinical trials may aid in characterising treatment efficacy and aid in the representation of patientreported goalconcordant care. As newtargeted therapies are emerging, pemphigus <a href=\"https:\/\/www.adooq.com\/efonidipine.html\">Efonidipine<\/a> clinical trials are increasing.7As these studies are being increasingly conducted, there is a greater need for standardisation of validated measurement tools to assess clinical endpoints. Two such tools include the autoimmune bullous skin disorder intensity score (ABSIS) and the Pemphigus Disease Area Index (PDAI), which are comprehensive scoring tools used to evaluate pemphigus disease severity.8Furthermore, serum screening is increasingly utilised to assess pemphigus disease severity. Particularly, antidesmoglein1 and antidesmoglein3 antibody levels can be used to distinguish pemphigus subtypes, characterise disease progression, and indicate response to treatment, though they should not be utilised in isolation. Immunoglobulins (particularly IgG levels and\/or IgM and IgA) can also be used to assess pemphigus severity, and antidrug antibodies allow for the monitoring of treatment efficacy and development of drug resistance.9,10 Other measures, such as investigator global assessment (IGA), disease activity index, the dose of corticosteroid and time until remission are also used. The utilization of dermatologyspecific questionnaires, such as the Dermatology Life Quality Index (DLQI) and autoimmune bullous quality of life (ABQOL) may aid in capturing pemphigusspecific psychosocial effects. The use of objective and subjective outcomes via a diverse subset of scales and questionnaires makes the compilation of data and intrastudy crosscomparisons challenging, particularly in rare diseases such as pemphigus where the number of patients is limited. Utilization of devices that are not validated may hinder study legitimacy and inadequately capture pemphigus clinical outcomes. Given the role of clinical research as evidence for informed clinical decisionmaking, analysing styles in pemphigus disease severity and QoL steps is necessary. Assessing the current landscape of these measuring tools may guide future questionnaire\/tool selection in future clinical trials to allow for improved compilation of data for more informed therapeutic decisionmaking for clinicians. In this scoping review, we aim to analyse.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\ufeffLimiting the number of disease severity and QoL questionnaires in use and standardising implementation can aid in assessing outcome measures across clinical trials and allow [&#8230;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[23],"tags":[],"class_list":["post-854","post","type-post","status-publish","format-standard","hentry","category-histamine-receptors"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>\ufeffLimiting the number of disease severity and QoL questionnaires in use and standardising implementation can aid in assessing outcome measures across clinical trials and allow for better data interpretation, comparability and clinical application of results - Discovery and characterization of Histamine-2 Receptor Antagonists<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/wmtc2006.com\/?p=854\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\ufeffLimiting the number of disease severity and QoL questionnaires in use and standardising implementation can aid in assessing outcome measures across clinical trials and allow for better data interpretation, comparability and clinical application of results - Discovery and characterization of Histamine-2 Receptor Antagonists\" \/>\n<meta property=\"og:description\" content=\"\ufeffLimiting the number of disease severity and QoL questionnaires in use and standardising implementation can aid in assessing outcome measures across clinical trials and allow [...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/wmtc2006.com\/?p=854\" \/>\n<meta property=\"og:site_name\" content=\"Discovery and characterization of Histamine-2 Receptor Antagonists\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-14T18:27:58+00:00\" \/>\n<meta name=\"author\" content=\"wpadmin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"wpadmin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/wmtc2006.com\\\/?p=854#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/wmtc2006.com\\\/?p=854\"},\"author\":{\"name\":\"wpadmin\",\"@id\":\"http:\\\/\\\/wmtc2006.com\\\/#\\\/schema\\\/person\\\/5a1d916d8ed9c89b34ac45c96f81e776\"},\"headline\":\"\ufeffLimiting the number of disease severity and QoL questionnaires in use and standardising implementation can aid in assessing outcome measures across clinical trials and allow for better data interpretation, comparability and clinical application of results\",\"datePublished\":\"2025-06-14T18:27:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/wmtc2006.com\\\/?p=854\"},\"wordCount\":783,\"articleSection\":[\"Histamine Receptors\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/wmtc2006.com\\\/?p=854\",\"url\":\"https:\\\/\\\/wmtc2006.com\\\/?p=854\",\"name\":\"\ufeffLimiting the number of disease severity and QoL questionnaires in use and standardising implementation can aid in assessing outcome measures across clinical trials and allow for better data interpretation, comparability and clinical application of results - Discovery and characterization of Histamine-2 Receptor Antagonists\",\"isPartOf\":{\"@id\":\"http:\\\/\\\/wmtc2006.com\\\/#website\"},\"datePublished\":\"2025-06-14T18:27:58+00:00\",\"author\":{\"@id\":\"http:\\\/\\\/wmtc2006.com\\\/#\\\/schema\\\/person\\\/5a1d916d8ed9c89b34ac45c96f81e776\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/wmtc2006.com\\\/?p=854#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/wmtc2006.com\\\/?p=854\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/wmtc2006.com\\\/?p=854#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"http:\\\/\\\/wmtc2006.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\ufeffLimiting the number of disease severity and QoL questionnaires in use and standardising implementation can aid in assessing outcome measures across clinical trials and allow for better data interpretation, comparability and clinical application of results\"}]},{\"@type\":\"WebSite\",\"@id\":\"http:\\\/\\\/wmtc2006.com\\\/#website\",\"url\":\"http:\\\/\\\/wmtc2006.com\\\/\",\"name\":\"Discovery and characterization of Histamine-2 Receptor Antagonists\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"http:\\\/\\\/wmtc2006.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"http:\\\/\\\/wmtc2006.com\\\/#\\\/schema\\\/person\\\/5a1d916d8ed9c89b34ac45c96f81e776\",\"name\":\"wpadmin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e57206ca88c051844b618224f501afdd8e9328b238000fd2f37bf30c03bcff14?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e57206ca88c051844b618224f501afdd8e9328b238000fd2f37bf30c03bcff14?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e57206ca88c051844b618224f501afdd8e9328b238000fd2f37bf30c03bcff14?s=96&d=mm&r=g\",\"caption\":\"wpadmin\"},\"sameAs\":[\"http:\\\/\\\/wmtc2006.com\"],\"url\":\"https:\\\/\\\/wmtc2006.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\ufeffLimiting the number of disease severity and QoL questionnaires in use and standardising implementation can aid in assessing outcome measures across clinical trials and allow for better data interpretation, comparability and clinical application of results - Discovery and characterization of Histamine-2 Receptor Antagonists","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/wmtc2006.com\/?p=854","og_locale":"en_US","og_type":"article","og_title":"\ufeffLimiting the number of disease severity and QoL questionnaires in use and standardising implementation can aid in assessing outcome measures across clinical trials and allow for better data interpretation, comparability and clinical application of results - Discovery and characterization of Histamine-2 Receptor Antagonists","og_description":"\ufeffLimiting the number of disease severity and QoL questionnaires in use and standardising implementation can aid in assessing outcome measures across clinical trials and allow [...]","og_url":"https:\/\/wmtc2006.com\/?p=854","og_site_name":"Discovery and characterization of Histamine-2 Receptor Antagonists","article_published_time":"2025-06-14T18:27:58+00:00","author":"wpadmin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"wpadmin","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/wmtc2006.com\/?p=854#article","isPartOf":{"@id":"https:\/\/wmtc2006.com\/?p=854"},"author":{"name":"wpadmin","@id":"http:\/\/wmtc2006.com\/#\/schema\/person\/5a1d916d8ed9c89b34ac45c96f81e776"},"headline":"\ufeffLimiting the number of disease severity and QoL questionnaires in use and standardising implementation can aid in assessing outcome measures across clinical trials and allow for better data interpretation, comparability and clinical application of results","datePublished":"2025-06-14T18:27:58+00:00","mainEntityOfPage":{"@id":"https:\/\/wmtc2006.com\/?p=854"},"wordCount":783,"articleSection":["Histamine Receptors"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/wmtc2006.com\/?p=854","url":"https:\/\/wmtc2006.com\/?p=854","name":"\ufeffLimiting the number of disease severity and QoL questionnaires in use and standardising implementation can aid in assessing outcome measures across clinical trials and allow for better data interpretation, comparability and clinical application of results - Discovery and characterization of Histamine-2 Receptor Antagonists","isPartOf":{"@id":"http:\/\/wmtc2006.com\/#website"},"datePublished":"2025-06-14T18:27:58+00:00","author":{"@id":"http:\/\/wmtc2006.com\/#\/schema\/person\/5a1d916d8ed9c89b34ac45c96f81e776"},"breadcrumb":{"@id":"https:\/\/wmtc2006.com\/?p=854#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/wmtc2006.com\/?p=854"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/wmtc2006.com\/?p=854#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"http:\/\/wmtc2006.com\/"},{"@type":"ListItem","position":2,"name":"\ufeffLimiting the number of disease severity and QoL questionnaires in use and standardising implementation can aid in assessing outcome measures across clinical trials and allow for better data interpretation, comparability and clinical application of results"}]},{"@type":"WebSite","@id":"http:\/\/wmtc2006.com\/#website","url":"http:\/\/wmtc2006.com\/","name":"Discovery and characterization of Histamine-2 Receptor Antagonists","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"http:\/\/wmtc2006.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"http:\/\/wmtc2006.com\/#\/schema\/person\/5a1d916d8ed9c89b34ac45c96f81e776","name":"wpadmin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e57206ca88c051844b618224f501afdd8e9328b238000fd2f37bf30c03bcff14?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e57206ca88c051844b618224f501afdd8e9328b238000fd2f37bf30c03bcff14?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e57206ca88c051844b618224f501afdd8e9328b238000fd2f37bf30c03bcff14?s=96&d=mm&r=g","caption":"wpadmin"},"sameAs":["http:\/\/wmtc2006.com"],"url":"https:\/\/wmtc2006.com\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/wmtc2006.com\/index.php?rest_route=\/wp\/v2\/posts\/854","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wmtc2006.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wmtc2006.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wmtc2006.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/wmtc2006.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=854"}],"version-history":[{"count":1,"href":"https:\/\/wmtc2006.com\/index.php?rest_route=\/wp\/v2\/posts\/854\/revisions"}],"predecessor-version":[{"id":855,"href":"https:\/\/wmtc2006.com\/index.php?rest_route=\/wp\/v2\/posts\/854\/revisions\/855"}],"wp:attachment":[{"href":"https:\/\/wmtc2006.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=854"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wmtc2006.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=854"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wmtc2006.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=854"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}